GET DAILY SIGNALSPersonalis (PSNL) Q3 2026 Earnings: MRD Testing and the Tempus Acquisition Take Center Stage
Key Takeaways
- Personalis is set to report third-quarter 2026 results after market close, with consensus estimates pointing to a net loss of roughly $0.26 per share.
- Wall Street anticipates revenue around $21.5 million, a notable increase from $14.5 million in the year-ago quarter.
- Attention will center on growth in minimal residual disease (MRD) testing, the genomic approach that identifies trace amounts of cancer remaining after treatment.
- The planned acquisition by Tempus AI at $16.25 per share continues to influence trading around the release.
- Full-year 2026 revenue guidance stands at $78 million to $80 million, which would reflect about 26% growth.
- For additional context on the ticker, review its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to discover AI-driven trading strategies and market signals.
Earnings Context and Its Significance
Personalis focuses on precision oncology through advanced genomic testing, with a particular emphasis on MRD detection. The company has been intentionally moving away from lower-margin enterprise work toward higher-value MRD testing, a shift that management believes will improve both revenue composition and profitability over time. This quarter provides a useful checkpoint on whether that transition is delivering sustained growth and better margins. The report also comes with the pending Tempus AI acquisition at $16.25 per share serving as an important backdrop, so any commentary on deal timing or integration will matter as much as the headline results.
Analyst Expectations
Consensus estimates call for a net loss of about $0.26 per share in the third quarter of 2026, compared with a $0.24 per share loss in the same period last year. Revenue is projected near $21.5 million, which would represent roughly 48% growth from $14.5 million a year earlier. In the most recent quarter, Personalis reported a $0.30 per share loss that was wider than the $0.26 consensus, while revenue of roughly $22.4 million exceeded expectations. For the full 2026 year, management has guided to revenue between $78 million and $80 million, with biopharma MRD revenue expected to more than double year over year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Investor focus ahead of the release is driven more by the Tempus AI acquisition than by quarterly results alone. The stock has risen roughly 64% over the past year and trades close to the $16.25 offer price, indicating positioning around deal completion. With a beta of about 2.3, Personalis exhibits notably higher volatility than the broader market, so surprises in results or deal updates could lead to larger price swings. Potential risks include a wider loss, softer MRD demand, or any indication of delays in the acquisition process. A solid quarter could strengthen confidence in the company’s independent growth path even as the merger advances.
Forward Outlook and Factors to Watch
Investors should monitor several forward indicators beyond the headline numbers. Growth in biopharma MRD revenue will be the clearest sign of whether the strategic pivot is succeeding, and management has indicated this segment should more than double year over year. Gross margin trends are also worth following, given recent compression tied to strategic investments and revenue-mix changes. Updates on Medicare reimbursement for clinical testing could provide additional color on margin outlook. The Tempus AI acquisition remains the primary catalyst, with any news on regulatory approvals or closing timelines likely to overshadow near-term operations for many holders. Finally, the company’s cash position, which exceeds $200 million, offers continued runway for MRD investment during the deal process.
Using Tickeron’s AI Tools in Research
In my own analysis, I often rely on Tickeron’s AI Screener to quickly filter opportunities in precision medicine and genomics. The tool lets me scan for technical patterns, fundamentals, and AI signals across thousands of stocks, helping surface relevant ideas without manual effort. It has become a regular part of how I compare names like PSNL to peers before earnings releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PSNL saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for PSNL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In 56 of the 62 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PSNL as a result. In 80 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PSNL turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PSNL moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PSNL crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PSNL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for PSNL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
Following a +0.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where PSNL advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PSNL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PSNL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.158) is normal, around the industry mean (65.876). P/E Ratio (-14.459) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (22.573) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PSNL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.
Industry MedicalSpecialties
Advertisement